I-Mab Bio­phar­ma to split US, Chi­na busi­ness­es to cut costs, mit­i­gate po­ten­tial risks

I-Mab Bio­phar­ma may have long tak­en pride in be­ing a Chi­na-based glob­al play­er, but from here on out, it wants to be known as a US-based biotech.

The com­pa­ny is carv­ing out its as­sets and busi­ness op­er­a­tions in Chi­na in­to a new en­ti­ty dubbed I-Mab Bio­phar­ma (Hangzhou) — which will be backed by a group of Chi­na-based in­vestors and head­ed by founder Jing­wu Zang. Ac­cord­ing to I-Mab, the move kills three birds with one stone: “stream­lin­ing the op­er­at­ing mod­el, re­duc­ing op­er­a­tional costs, and mit­i­gat­ing po­ten­tial as­so­ci­at­ed risks.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER